Terumo India, the Indian subsidiary of Japan’s Terumo Corporation, has announced the launch of its latest-generation FineCross™ M3 Coronary Micro-Guide Catheter in India. The new device sets a higher benchmark for percutaneous coronary intervention (PCI) by providing cardiologists with superior crossing ability, guidewire support, and navigability—especially in managing complex coronary lesions that often determine procedural success.
With coronary artery disease (CAD) remaining the leading cause of death in India and a growing number of patients presenting with challenging and complex lesions, the need for advanced interventional tools has never been greater. The FineCross™ M3 aims to address this gap by enabling cardiologists to perform procedures that are more efficient, predictable, and safe, thereby improving both clinical outcomes and operator confidence.
“Innovation at Terumo India is always guided by enabling physicians to deliver the best possible care to patients. With the launch of FineCross™ M3, we are proud to bring a globally trusted advancement in interventional cardiology to India. This milestone reflects not only our commitment to strengthening cardiovascular care in the country, but also Our Promise ‘Unwavering commitment to patients’ that lies at the heart of everything we do,” said Shishir Agarwal, President and Managing Director, Terumo India.
The FineCross™ M3 integrates Terumo’s engineering heritage with new design enhancements that directly address real-world PCI challenges, reinforcing the company’s dedication to continuous innovation in cardiovascular care.
Also Read
“FineCross™ M3 represents more than just a product launch; it reflects our continued focus on advancing cardiovascular care in India in line with Terumo’s mission of contributing to society through healthcare. Through globally trusted innovations, we aim to empower physicians in delivering better patient outcomes and create a meaningful impact where it matters most,” said Nitin Stephen Abel, Senior Director, Terumo Interventional Systems, Terumo India.
The introduction of FineCross™ M3 adds to Terumo India’s expanding portfolio of advanced interventional solutions, further cementing its leadership in shaping the future of cardiovascular care across the country.
